Pharmosa Biopharm Inc. (TPEX:6875)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
38.40
+0.40 (1.05%)
Apr 28, 2026, 1:30 PM CST
-25.58%
Market Cap 4.96B
Revenue (ttm) 67.27M
Net Income (ttm) -383.85M
Shares Out 129.15M
EPS (ttm) -2.97
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 78,033
Average Volume 97,626
Open 38.85
Previous Close 38.00
Day's Range 37.70 - 38.85
52-Week Range 35.20 - 65.00
Beta 0.28
RSI 50.65
Earnings Date May 11, 2026

About Pharmosa Biopharm

Pharmosa Biopharm Inc., a biotechnology company, focuses on developing drugs in Taiwan. It develops L606, an inhalation/device combination for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; and L608, an inhalation/device combination for the treatment of pulmonary vascular disease. The company was formerly known as Pharmosa Limited and changed its name to Pharmosa Biopharm Inc. in October 2016. Pharmosa Biopharm Inc. was founded in 2000 and is headquartered in Taipei, Taiwan... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 40
Stock Exchange Taipei Exchange
Ticker Symbol 6875
Full Company Profile

Financial Performance

In 2025, Pharmosa Biopharm's revenue was 67.27 million, a decrease of -59.86% compared to the previous year's 167.57 million. Losses were -383.85 million, 130.3% more than in 2024.

Financial Statements

News

There is no news available yet.